Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

Molecular Cancer Therapeutics

Volumn 6, Issue 9, 2007, Pages 2429-2440

  Qin, Yuxin ^a   Meng, Linghua ^a   Hu, Chaoxin ^a   Duan, Wenhu ^a   Zuo, Zhili ^a   Lin, Liping ^a   Zhang, Xiongwen ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOXORUBICIN; ETOPOSIDE; GAMBOGIC ACID; PROTEIN C JUN; RESIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CATALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DOWN REGULATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STABILITY; FEMALE; GARCINIA; GARCINIA HURBURYI; HUMAN; HUMAN CELL; HYDROLYSIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; TARGET CELL; TUMOR CELL;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLOW CYTOMETRY; GENES, MDR; HELA CELLS; HUMANS; HYDROLYSIS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PHOSPHORYLATION; RNA INTERFERENCE; SURFACE PLASMON RESONANCE; TUMOR STEM CELL ASSAY; XANTHONES;

EID: 34748925888     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0147     Document Type: Article

References (44)

1. Hsieh T. DNA topoisomerases. Curr Opin Cell Biol 1990;2:461-3.
2. Giles GI, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 2005;1:383-94.
3. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
4. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167-81.
5. Jensen PB, Sorensen BS, Demant EJ, et al. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)- methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 1990;50:3311-6.
6. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJ. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1- yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993;46:389-93.
7. Jensen PB, Sehested M. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 1997;54:755-9.
8. Zhang HZ, Kasibhatla S, Wang Y, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 2004;12:309-17.
9. Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci U S A 2005;102:12095-100.
10. Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004;27:1769-74.
11. Yu J, Guo QL, You QD, et al. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemother Pharmacol 2006;58:434-43.
12. Guo QL, Lin SS, You QD, et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci 2006;78:1238-45.
13. Jun Y, Guo QL, You QD, et al. Gambogic acid induced G2/M phase cell cycle arrest via disturbing CDK7 mediated phosphorylation of CDC2/P34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2006;28:632-8.
14. Yang F, Chen Y, Duan W, Zhang C, Zhu H, Ding J. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer 2006;119:1184-93.
15. Meng LH, Zhang JS, Ding J. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 2001;62:733-41.
16. Osheroff N, Zechiedrich EL. Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry 1987;26:4303-9.
17. Zechiedrich EL, Christiansen K, Andersen AH, Westergaard O, Osheroff N. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry 1989;28:6229-36.
18. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 1990;122:86-94.
19. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002;62:5248-53.
20. Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, Nakano H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992;31:12069-75.
21. Perrin D, van Hille B, Barret JM, et al. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000;59:807-19.
22. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 1998;273:17643-50.
23. Osheroff N, Shelton ER, Brutlag DL. DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem 1983;258:9536-43.
24. Hu T, Sage H, Hsieh TS. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. J Biol Chem 2002;277:5944-51.
25. Hu CX, Zuo ZL, Xiong B, et al. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol 2006;70:1593-601.
26. Wei H, Ruthenburg AJ, Bechis SK, Verdine GL. Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J Biol Chem 2005;280:37041-7.
27. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999;18:188-97.
28. Jensen PB, Jensen PS, Demant EJ, et al. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 1991;51:5093-9.
29. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 1994;91:1781-5.
30. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
31. Binaschi M, Capranico G, Dal Bo L, Zunino F. Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol 1997;51:1053-9.
32. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000;64:221-53.
33. Brana MF, Cacho M, Gradillas A, de Pascual-Teresa B, Ramos A. Intercalators as anticancer drugs. Curr Pharm Des 2001;7:1745-80.
34. Montecucco A, Pedrali-Noy G, Spadari S, Zanolin E, Ciarrocchi G. DNA unwinding and inhibition of T4 DNA ligase by anthracyclines. Nucleic Acids Res 1988;16:3907-18.
35. Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 2003;3:339-53.
36. Sorensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol 1992;228:778-86.
37. Robinson MJ, Corbett AH, Osheroff N. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry 1993;32:3638-43.
38. Cornarotti M, Tinelli S, Willmore E, et al. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIa (p170) and IIβ (p180). Mol Pharmacol 1996;50:1463-71.
39. Capranico G, Giaccone G, D'Incalci M. DNA topoisomerase II poisons and inhibitors. Cancer Chemother Biol Response Modif 1999;18:125-43.
40. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998;1400:155-71.
41. Gormley NA, Orphanides G, Meyer A, Cullis PM, Maxwell A. The interaction of coumarin antibiotics withfrag ments of DNA gyrase B protein. Biochemistry 1996;35:5083-92.
42. Gilbert EJ, Maxwell A. The 24 kDa N-terminal sub-domain of the DNA gyrase B protein binds coumarin drugs. Mol Microbiol 1994;12:365-73.
43. Vilain N, Tsai-Pflugfelder M, Benoit A, Gasser SM, Leroy D. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIα. Nucleic Acids Res 2003;31:5714-22.
44. Jensen LH, Wessel I, Moller M, Nitiss JL, Sehested M, Jensen PB. N-terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance. FEBS Lett 2000;480:201-7.